Group items tagged

Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the Program Announcement, and not on the amount of the budget. The current Program Announcement discusses the Breakthrough Award Level 3. Funding Levels 1, 2, and 4 are available under other Program Announcements (W81XWH-20-BCRP- BTA12-2 for Levels 1 and 2 and W81XWH-20-BCRP-BTA4-2 for Level 4). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award Program Announcements before submitting the pre- application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.

(RFA-NS-19-025 is being reissued to accommodate an additional receipt date). The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers (hubs) of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIHs Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers (hubs). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites (spokes). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-18-036) and Data Coordinating Center (RFA-NS-18-035). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

The National Cancer Institute supports the development of cancer-relevant technologies that would be suitable for global health environments with limited resources. NCI is announcing its intent to reissue a Funding Opportunity Announcement (FOA) soliciting applications for the development of new technologies/devices and/or adaptation of existing technologies/devices for cancer detection/diagnosis and treatment to be tested and ultimately implemented in low- and low-middle-income countries (LMICs), as listed by World Bank

This Funding Opportunity Announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer (or a related group of cancers). For the purpose of this funding announcement, cancers derived from the same organ system (i.e., group of organs that perform common function) are considered related. Examples of such organ systems include gastro-intestinal, endocrine, circulatory, and other biological systems.

This Funding Opportunity Announcement (FOA) announces an opportunity for eligible investigators receiving research funding from The National Institutes of Health (NIH) to request administrative supplement support. The "parent" awards and the proposed administrative supplements must be in areas of cancer, allergy, immunology, and/or infectious diseases (including HIV/AIDS and its co-morbidities). The overall goal of this supplement program is to enhance ongoing research efforts through collaborations with Brazilian scientists in these scientific areas under the new U.S.-Brazil Collaborative Biomedical Research Program.  

This Funding Opportunity Announcement (FOA) announces an opportunity for eligible investigators receiving research funding from The National Institutes of Health (NIH) to request administrative supplement support. The parent awards and the proposed administrative supplements must be in areas of cancer, allergy, immunology, and/or infectious diseases (including HIV/AIDS and its co-morbidities). The overall goal of this supplement program is to enhance ongoing research efforts through collaborations with Brazilian scientists in these scientific areas under the new U.S.-Brazil Collaborative Biomedical Research Program.

This Funding Opportunity Announcement (FOA) invites cooperative agreement (U54) applications for the implementation of Comprehensive Partnerships between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI-designated Cancer Centers (CC). The purpose of this limited competition funding opportunity announcement (FOA) is to continue fostering and supporting intensive collaborations among investigators at ISUPS and CCs in order to develop stronger national cancer programs aimed at understanding the reasons behind the significant cancer disparities and related impacts on these populations. This FOA is intended for: (1) supporting active Comprehensive Partnerships under the U54 mechanism or inactive Comprehensive Partnerships but formerly supported by the U54 mechanism; and (2) elevating the promising U56 partnerships and other similar partnerships to the comprehensive status.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are: Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome. Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement/Funding Opportunity. An additional funding level, Funding Level 3, is available under a different Program Announcement (W81XWH-15-BCRP-BREAKTHROUGH2_FL3). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: * Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required. * Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable. Partnering PI Option: The Breakthrough Award encourages applications that includ

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and appropriate follow-up care, optimizing the delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation G: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites multiple Program Director/Principle Investigator (multi-PD/PI) U01 application for projects aimed at identifying best practices to improve case ascertainment and follow-up care of hereditary cancers, with the goal of improving prevention and detection.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.

The purpose of the U.S.-China Program for Biomedical Collaborative Research is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Chinese researchers in the areas of cancer, environmental health, heart disease, blood disorders, diseases of the eye and visual system, mental health, and neurological disorders. Partnering U.S. and Chinese investigators must work jointly to submit identical applications to NIH and National Natural Science Foundation of China (NSFC), respectively. U.S. investigators must respond to the announcement from NIH, including the Chinese application as an attachment, and Chinese investigators must respond to a separate funding announcement from NSFC, including the NIH application as an attachment.

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for well-developed research projects using the NIH R01 funding mechanism. The companion FOA, RFA-CA-18-014, is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

The Fusion Energy Sciences (FES) program of the Office of Science (SC) and the Defense Program (DP) of the National Nuclear Security Administration (NNSA), both of the U.S. Department of Energy (DOE), jointly announce their interests in receiving grant applications for new awards and grant renewals for research in the SC-NNSA Joint Program in High-Energy-Density (HED) laboratory plasmas. All individuals or groups planning to submit applications for new or renewal funding in Fiscal Year 2018 should submit in response to this Funding Opportunity Announcement (FOA). The specific areas of interest are: 1. HED Hydrodynamics 2. Radiation-Dominated Dynamics and Material Properties 3. Magnetized HED Plasma Physics 4. Nonlinear Optics of Plasmas and Laser-Plasma Interactions 5. Relativistic HED Plasmas and Intense Beam Physics 6. Warm Dense Matter 7. High-Z, Multiply Ionized HED Atomic Physics 8. Diagnostics for HED Laboratory Plasmas More specific information on each area of interest is outlined in the general and program specific supplementary information provided.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) that is intended to accelerate cancer research. The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/prevention-screening-working-group-report.pdf) Recommendation G (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel#ui-id-3 ): "Sponsor initiatives to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development and conduct implementation science research to accelerate development, testing, and broader adoption of proven strategies to significantly reduce cancer risk and address cancer health disparities in these areas." This Funding Opportunity Announcement invites U01 applications for projects that develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer so that they can make informed clinical risk management decisions.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. These studies should generate validated high-quality preclinical data on the effects of molecular therapeutics when added to standard-of-care therapies for solid tumors. The specific purpose is to provide a more rational basis for prioritizing those NCI-supported investigational new drugs or agents (INDs) most likely to have clinical activity with chemo-radiotherapy. The overall goal is to accelerate the pace at which combined modality treatments with greater efficacy are identified and incorporated into standard practices for treatments of patients with solid tumors.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.